Professor Hao Zeng: Precision Treatment of mCRPC Through the Lens of Mutation Profiles in Chinese Patients — Biomarker Analysis from TALAPRO-2 and Implications for First-Line Treatment Decisions
At the 2026 Congress of the European Society for Medical Oncology (ESMO), a biomarker analysis of the Chinese cohort from TALAPRO-2 was presented as a poster. Understanding the differences in radiographic progression-free survival (rPFS) between the Chinese cohort and the global population, and translating molecular testing results into treatment decisions, are important issues in the individualized management of metastatic castration-resistant prostate cancer (mCRPC).









